Control of HIV Infection Dynamics

IEEE Control Systems

Volumn 28, Issue 2, 2008, Pages 28-39

  Chang, Hyeygjeon ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOTHERAPY; CONTINUOUS TIME SYSTEMS; FEEDBACK CONTROL; MATHEMATICAL MODELS; OPTIMAL CONTROL SYSTEMS; SCHEDULING ALGORITHMS;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG SCHEDULING METHOD; HUMAN IMMUNODEFICIENCY VIRUS; OPEN-LOOP CONTROL;

CONTROL THEORY;

EID: 41949127007     PISSN: 1066033X     EISSN: None     Source Type: Journal    
DOI: 10.1109/MCS.2007.914692     Document Type: Article

References (30)

1. M. Nowak and R. May, Virus Dynamics. New York, 2000.
2. I. Craig and X. Xia, “Can HIV/AIDS be controlled?,’ IEEE Contr. Syst. Mag., vol. 25, pp. 80–83, Feb. 2005.
3. L. Wein, S. Zenios, and M. Nowak, “Dynamic multidrug therapies for HIV: A control theoretic approach,” J. Theoretical Biol., vol. 185, pp. 15-29,1997.
4. D. Kirschner, S. Lenhart, and S. Serbin, “Optimal control of the chemotherapy of HIV,” J. Mathematical Biol., vol. 35, pp. 775-792,1997.
5. M. Brandt and G. Chen, “Feedback control of a biodynamical model of HIV-1,” IEEE Trans. Biomed. Eng., vol. 48, no. 7, pp. 754–759, 2001.
6. S.S. Ge, Z. Tian, and T.H. Lee, “Nonlinear control of a dynamic model of HIV-1,” IEEE Trans. Biomed. Eng., vol. 52, no. 3, pp. 353–361, 2005.
7. R. Culshaw, S. Ruan, and R. Spiteri, “Optimal HIV treatment by maximising immune response,” J. Mathematical Biol., vol. 48, pp. 545–562, 2004.
8. D. Wodarz and M. Nowak, “Specific therapy regimes could lead to long-term immunological control of HIV,” Proc. Nat. Acad. Sci., vol. 96, no. 25, pp. 14464-14469,1999.
9. J. Lisziewicz, E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, and F. Lori, “Control of HIV despite the discontinuation of antiretroviral therapy,” New Eng. J. Med., vol. 340, no. 21, pp. 1683-1684,1999.
10. B. Autran and G. Carcelain, “AIDS: Boosting immunity to HIV-Can the virus help?” Science, vol. 290, no. 5493, pp. 946–949, 2000.
11. D. Wodarz, “Helper-dependent vs. helper-independent CTL responses in HIV infection: Implications for drug therapy and resistance,” J. Theoretical Biol., vol. 213, pp. 447–459, 2001.
12. D. Wodarz and M. Nowak, “Mathematical models of HIV pathogenesis and treatment,” BioEssays, vol. 24, pp. 1178–1187, 2002.
13. R. Zurakowski and A. Teel, “Enhancing immune response to HIV infection using MPCbased treatment scheduling,” in Proc. American Control Conf., Denver, CO, 2003, pp. 1182–1187.
14. R. Zurakowski and A. Teel, “A model predictive control based scheduling method for HIV therapy,” J. Theoretical Biol., vol. 238, pp. 368–382, 2006.
15. H. Shim, S. Han, I. Jeong, C. Chung, S. Nam, and J. Seo, “Optimal scheduling of drug treatment for HIV infection: continuous dose control and receding horizon control,” Int. J. Contr., Automat. Syst., vol. 1, no. 3, pp. 282–288, 2003.
16. H. Chang, H. Shim, and J. Seo, “Control of immune response of HIV infection model by gradual reduction of drug dose,” in Proc. Conf. Decision Control, Nassau, Bahamas, 2004, pp. 1048–1054.
17. A. Perelson and P. Nelson, “Mathematical analysis of HIV-1 dynamics in vivo,” SIAM Rev., vol. 41, no. 1, pp. 3-44,1999.
18. H. Chang, N. Jo, and H. Shim, “Gradual reduction of drug dosage on an HIV infection model with helper-independent CTL,” J. Contr., Automat. Syst. Eng., vol. 10, no. 12, pp. 1148–1154, 2004.
19. A. Palfreeman, M. Youle, and C. Farthing, Drugs in HIV and AIDS, 2nd ed. New York: Wiley, 1998.
20. K. Alcorn, A. Poppa, and M. Nicholson, HIV and AIDS Treatments Directory, 16th ed. 1999.
21. M. Piatak, M. Saag, L. Yang, S. Clark, J. Kappes, K. Luk, B. Hahn, G. Shaw, and J. Lifson, “Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction,” AIDS, vol. 7, pp. 65-71,1993.
22. M. Mascio, R. Ribeiro, M. Markowitz, D. Ho, and A. Perelson, “Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy,” Math. Biosci., vol. 188, pp. 47-62, 2004.
23. H. Chapel, M. Haeney, S. Misbah, and N. Snowden, Essentials of Clinical Immunology, 4th ed. Oxford, U.K.: Blackwell Science, 1999.
24. M. Sande and P. Volberding, The Medical Management of AIDS, 6th ed. Philadelphia, PA: Saunders, 1999.
25. L. Herzenberg, D. Parks, B. Sahaf, O. Perez, M. Roederer, and L. Herzenberg, “The history and future of the fluorescence activated cell sorter and flow cytometry: A view from Stanford,” Clin. Chem., vol. 48, no. 10, pp. 1819–1827, 2002.
26. X. Xia, “Estimation of HIV/AIDS parameters,” Automatica, vol. 39, pp. 1983–1988, 2003.
27. X. Xia and C. Moog, “Identifiability of nonlinear systems with applications to HIV/AIDS models,” IEEE Trans. Automat. Contr., vol. 48, no. 2, pp. 330–336, 2003.
28. S. Bonhoeffer, M. Rembiszewski, G. Ortiz, and D. Nixon, “Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection,” AIDS, vol. 14, pp. 2313–2322, 2000.
29. J. Kutch and P. Gurfil, “Optimal control of HIV infection with a continuously-mutating viral population,” in Proc. American Control Conf., Anchorage, AK, 2002, pp. 4033–4038.
30. J. Kimball, “The Fluorescence-Activated Cell Sorter” May 2006 [Online]. Available: http://user.rcn.com/jkimball.ma.ultranet/BiologyPages/ F/FACS.html